文献速递临床试验与 GCP基础与转化研究

拉考沙胺治疗周围神经病理性疼痛:随机、安慰剂对照、表型分层试验的研究方案

Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial.
PubMed 文献 · Trials · 2019-10-11

这是一项多中心、随机、双盲、安慰剂对照、平行、2期、概念验证、表型分层研究方案,计划纳入108例周围神经病理性疼痛患者,按2:1随机接受拉考沙胺或安慰剂治疗12周(拉考沙胺至400 mg/天)。主要目的是在符合方案人群中比较有和无易激惹伤害感受器表型患者从基线至治疗最后一周每日平均疼痛强度评分均值的变化;支持性目的为比较两种表型中拉考沙胺与安慰剂的效应。

要点

  • 研究纳入108例周围神经病理性疼痛患者,按2:1随机接受拉考沙胺或安慰剂治疗12周。
  • 拉考沙胺剂量至400 mg/天,主要分析在符合方案人群中进行。
  • 主要目的为比较有和无易激惹伤害感受器表型患者疼痛评分均值变化。

核心结论

  • 研究将检验基于表型的个体化治疗概念,预期为拉考沙胺治疗周围神经病理性疼痛的有用性提供重要信息。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行、2期、概念验证、表型分层研究。
  • 计划纳入108例周围神经病理性疼痛患者,按2:1随机接受拉考沙胺或安慰剂治疗12周,拉考沙胺剂量至400 mg/天。
  • 主要分析在符合方案人群中进行,比较有和无易激惹伤害感受器表型患者从基线至治疗最后一周每日平均疼痛强度评分均值的变化。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要目的为在符合方案人群中比较有和无易激惹伤害感受器表型患者从基线至治疗最后一周每日平均疼痛强度评分均值的变化。
  • 支持性目的为比较两种表型中拉考沙胺与安慰剂的效应。
  • 次要和三级结局包括患者总体印象变化、疼痛缓解、30%和50%疼痛减轻的存在、睡眠障碍、抑郁和焦虑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuropathic pain is a common pain condition that has a major negative impact on health-related quality of life. However, despite decades of research, it remains difficult to treat neuropathic pain. Lacosamide is a sodium-channel blocker that is efficacious in animal models of neuropathic pain. In humans, its effect in neuropathic pain is inconclusive, based on inconsistent results and very large placebo responses. Previous trials have not used patient stratification or looked for predictors for response. METHODS: This study will be conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel, phase 2, proof-of-concept, phenotype-stratified study. The study will enroll 108 patients with peripheral neuropathic pain who will be randomized to a 12-week treatment with lacosamide or placebo up to 400 mg/day in a 2:1 ratio. The primary objective is to compare the change in the mean value of the patients' daily ratings of average pain intensity from baseline to the last week of treatment in patients with and without the irritable nociceptor phenotype in the per-protocol population. A supportive objective is to compare the effect of lacosamide with that of placebo in the two phenotypes. Secondary and tertiary outcomes include the Patient Global Impression of Change, pain relief, presence of 30% and 50% pain reduction, sleep disturbance, depression, and anxiety. DISCUSSION: We will examine the concept of individualized therapy based on phenotyping, and expect that this study will provide important information on the usefulness of lacosamide in the treatment of peripheral neuropathic pain. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03777956 . Registered on 18 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Carmland ME, Kreutzfeldt M, Holbech JV, et al. Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial. Trials. 2019. PMID: 31604475. doi:10.1186/s13063-019-3695-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。